Abstract:535 Background: Clinical trials suggest that adjuvant radiotherapy (RT) may be omitted in women aged ≥65 with early-stage, hormone-receptor positive breast cancer provided completion of 5 years of endocrine therapy (ET). However, at the time of RT consult, it is often unknown whether the patient will start ET, or will start ET but not complete 5 years, either of which, if known in advance, would alter RT recommendations. We studied a cohort of patients who would have been eligible for these trials to examine which factors were related to declining or discontinuing ET. Methods: Using a prospectively maintained institutional database, we identified patients age ≥65 who underwent surgery between 2010 and 2017 with stage I breast cancer, hormone receptor positive. Missing data were replaced using multiple imputation. Recurrence statistics were calculated using Kaplan-Meier analysis. Multivariate (MVA) logistic regression was used to assess which factors were associated with not starting or discontinuing ET. Results: We identified 590 patients who met eligibility criteria. 453 (76.8%) patients started ET, of whom 315 (69.5%) completed at least 5 years, 84 (18.5%) stopped ET before 5 years, and 54 patients (11.9%) were lost to follow up. Median follow up was 67.2 months. Among the 137 patients who did not start ET, the most common reasons were osteopenia or osteoporosis (27.7%), arthritis (18.2%), and declined consultation with medical oncology (15.3%). On MVA, not starting ET was significantly associated with older age (OR 1.10, p < 0.0001), osteopenia (OR 2.27, p = 0.005) or osteoporosis (OR 3.82, p = 0.009), or not undergoing radiation (OR 1.92, p = 0.006) or chemotherapy (OR 6.45, p = 0.02). The most common reason for stopping ET was joint pain (50.0%), with other reasons including hot flashes (10.7%) and fatigue (7.1%). Not completing 5 years of ET was significantly associated with older age (OR 1.09, p = 0.002) and prior/current smoking history (OR 1.75, p = 0.037), while patients whose marital status was single or never married were significantly more likely to complete 5 years of ET (OR 0.26, p = 0.019). Recurrence-free survival was lower among the group which never started ET (p < 0.0001) or which stopped ET before 5 years (p < 0.0001) as compared to those who completed 5 years, with 5-year recurrence-free survival of 97.5% (95% CI: 95.6-99.3) for patients who completed 5 years of ET, compared to 88.7% (95% CI: 82.5-95.4) for those who did not undergo ET and 87.6% (95% CI: 80.4-95.6) for those who started ET but did not complete 5 years. Conclusions: Patients who are older, have osteopenia/osteoporosis, or who have declined prior treatment such as chemotherapy or RT are more likely not to start ET, while patients who are older or prior/current smokers are more likely to discontinue ET after starting and single / never married patients are more likely to complete ET. These factors may be used to guide discussion of omission of adjuvant radiotherapy.

Efficient GCD functions in SQL

EFFECT OF ADJUVANT ENDOCRINE THERAPY ON ESTROGEN RECEPTOR-NEGATIVE, PROGESTERONE RECEPTOR-POSITIVE AND HER2 NEGATIVE BREAST CANCER PATIENTS

Factors Influencing Adherence to Adjuvant Endocrine Therapy After Breast Cancer Surgery

[Efficacy of Adjuvant Endocrine Therapy in Breast Cancer Patients with a Positive-to-negative Switch of Hormone Receptor Status after Neoadjuvant Chemotherapy].

Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management

Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases

Initiation of Oral Endocrine Therapy and Survival Benefit Among Women with Early-Stage Breast Cancer

Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: A systematic review

Adherence Status to Adjuvant Endocrine Therapy in Chinese Women with Early Breast Cancer and Its Influencing Factors: A Cross‐sectional Survey

Social Characteristics and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women With Breast Cancer

Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients

Adherence, clinical benefits, and adverse effects of endocrine therapies among women with nonmetastatic breast cancer in developing countries: A systematic review and meta-analysis

Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis

Assessment of endocrine therapy adherence in a nurse-led cancer survivorship clinic: Results from the Linking You to Support and Advice (LYSA) trial.

Adherence behaviours in breast cancer patients at risk of cardiovascular disease

Abstract ED01-01: Optimizing endocrine therapy in premenopausal women

The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation

Adherence to adjuvant hormonal therapy in breast cancer patients

Adherence to Endocrine Therapy in Patients with Hormone Receptor-Positive Early-Stage Breast Cancer: a Retrospective Study.

Abstract PO3-01-14: Impact of detection mode, tumor characteristics and additional treatment on adherence to adjuvant endocrine therapy after breast cancer in Sweden

Predicting completion of endocrine therapy for older patients with early-stage breast cancer.